# Correction: Bajbouj et al. Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer. Int. J. Mol. Sci. 2022, 23, 4408

**Authors:** Khuloud Bajbouj, Rizwan Qaisar, Mohammed A. Alshura, Zeinab Ibrahim, Mohamad B. Alebaji, Amenah W. Al Ani, Hanadi M. Janajrah, Mariah M. Bilalaga, Abdelrahman I. Omara, Rebal S. Abou Assaleh, Maha M. Saber-Ayad, Adel B. Elmoselhi

PMC · DOI: 10.3390/ijms27020743 · 2026-01-12

## Full-text entities

- **Genes:** KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}
- **Diseases:** Breast Cancer (MESH:D001943)
- **Chemicals:** Lenvatinib (MESH:C531958), Regorafenib (MESH:C559147)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12840838/full.md

---
Source: https://tomesphere.com/paper/PMC12840838